Loading...
Loading...
BioLineRx
BLRX announced today that it has successfully completed the
pre-clinical development of BL-8020, an orally available,
interferon-free treatment for the Hepatitis C virus (HCV), and plans to
commence a Phase I/II safety and efficacy study for BL-8020 in Europe
during the first quarter of 2013.
Since in-licensing BL-8020 in January 2012, BioLineRx has successfully
completed a number of pre-clinical studies with the therapy. The data
package is now ready for the regulatory submissions required to begin
the clinical phase of development. BioLineRx is currently engaged in the
regulatory submission process and expects to receive approval from the
regulatory authorities by the end of this year.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in